NATCO Pharma has received EIR from the USFDA for its FDF manufacturing plant located in Parawada, Visakhapatnam, Andhra Pradesh. The USFDA had conducted an inspection at the facility from August 17 to August 21, 2026 and concluded the inspection with 4 observations in the Form-483. Now, USFDA has classified that inspection as Voluntary Action Indicated (VAI).
NATCO Pharma develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products.